Dallas Conference • March 24-25, 2017

The objective of the conference series is to deliver a comprehensive educational update highlighting the most clinically relevant advances in chronic liver and gastrointestinal (GI) diseases. The 1.5-day conferences cover topics ranging from upper GI disorders, viral hepatitis, cirrhosis, inflammatory bowel disease and irritable bowel syndrome.

Welcome/Introduction• Mack Mitchell, MD, and Lawrence R. Schiller, MD

Emerging hepatitis C (HCV) therapies-2017/2018• Fred Poordad, MD

Complications of cirrhosis: hepatic encephalopathy, ascites and variceal bleeding• Kimberly Brown, MD

Does curing HCV lead to HBV reactivation and higher risk of hepatocellular carcinoma (HCC)?• Jordan Feld, MD

HCC: Update on role of metabolic syndrome, screening and treatment• Hashem El-serag, MD, MPH

Q&A/Panel Discussion•

Advances in opioid-induced constipation management• Brooks Cash, MD

Fecal incontinence: Sealing the leak• Satish Rao, MD

Diarrhea: Managing exocrine pancreatic insufficiency (EPI), irritable bowel syndrome (IBS)
and small bowel bacterial overgrowth (SIBO)• Lawrence R. Schiller, MD

Q&A/Panel Discussion•

Diagnosis and management of primary biliary cholangitis (PBC)• Kris Kowdley, MD

Advances in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)• Naim Alkhouri, MD

Management of drug-induced liver injury (DILI)• Mack Mitchell, MD

Q&A/Panel Discussion•

Gastroparesis 2017-There is effective therapy and prevention is at hand• Richard McCallum, MD

Endoscopy in obesity: balloons and other devices• Shelby Sullivan, MD

Barrett's esophagus and esophageal cancer-Why can't we have more of an impact?• Joel Richter, MD

Q&A/Panel Discussion•

Management of celiac disease• Joseph Murray, MD

Preparing for the expanded use of biosimilars in inflammatory bowel disease (IBD)• Thomas Ullman, MD

Should chromoendoscopy be the standard for surveillance of colitis?• Themistocles Dassopoulos, MD

Q&A/Panel Discussion•